Elekta Demonstrates Comprehensive Range of Cancer Management Solutions at 2012 Arab Health Congress and Exhibition

DUBAI, United Arab Emirates, Jan. 27, 2012 /PRNewswire/ – An estimated 72,000 healthcare professionals gathered at the Dubai World Trade Centre Jan. 23-26 for the 2012 Arab Health Congress and Exhibition. The meeting also provided the framework for the 2nd Multi-Disciplinary Approach to Cancer Therapy Conference.

During the exhibition, Elekta demonstrated advanced solutions ranging from conventional radiation therapy with Elekta Compact™* to stereotactic neurosurgery with Leksell Gamma Knife® Perfexion™, products that provide clinicians with the tools to save and improve the lives of individuals with cancer. In addition, for the first time at Arab Health, Elekta presented advanced brachytherapy solutions.

The theme of the Elekta exhibit was "Experience the Elekta Difference," which emphasizes the company's commitment to increasing the user's clinical confidence by simplifying the variables in treatment planning, patient setup, verification and delivery.

"Elekta was honored to attend Arab Health once again as a Gold Sponsor for the 2nd Multi-Disciplinary Approach to Cancer Therapy Conference," says Nabil Elias Romanos, Elekta's Vice President, Eastern Europe and Middle East. "We enjoyed heavy booth traffic and were gratified by the interest in our entire product portfolio, including our brachytherapy solutions. Many of the discussions with hospital administrators and clinicians revolved around key partnerships in the regions, supported by education, training and clinical collaboration."

In 2012, Elekta will increase its presence in the region, after having already expanded its Dubai office to better serve customers and partners.

According to World Health Organization (WHO), cancer is the fourth-ranked cause of death in the wider Middle East Region. The top five cancers in the region, when males and females are combined, are breast, bladder, lung, oral and colon cancer. In addition, the largest increase in cancer incidence in the WHO regions in the next 15 years is likely to be in the wider Middle East Region.

"The unmet need of cancer care will continue to drive demand in Eastern Europe and the Middle East," Romanos adds. "In these regions, Elekta is committed to providing meaningful support over the wide spectrum of cancer management, combined with personalized training, as well as scalable offerings and services."

For more information on Elekta solutions, visit www.elekta.com/experience.

*Elekta Compact™ is not available for sale or distribution in all regions. Please contact your local Elekta representative or authorized distributor for further details.

About Elekta
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,300 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.

SOURCE Elekta

Suggested Articles

While Lilly's 2018 launch Emgality is approved to prevent migraines, Reyvow is intended to treat them as they occur.

ICER's new draft review of RA drugs takes a different approach, reflecting how physicians treat the disease and the time horizon that's considered.

Johnson & Johnson is facing multibillion-dollar liabilities in thousands of talc and opioid cases. But that's not such a bad thing, one analyst said.